Place of drug therapy in the prevention and treatment of bone complications of prostate cancer


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Bone complications of prostate cancer are serious problem faced by both patients and clinicians. Prevention of bone complications remains one of the major challenges for oncourologists. With the advent of new drugs, treatment options are gradually extending; furthermore, effectiveness of the treatment also increases. The use of bisphosphonates, particularly zoledronic acid, is the treatment of choice for the prevention of bone complications in patients with prostate cancer. However, the high efficacy of denosumab in prevention of bone complications and its effect on the tumor process gives the way for thinking about the preferability of treatment.

全文:

受限制的访问

参考

  1. Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные заболевания в России в 2009 году (заболеваемость и смертность).
  2. Liao J., Schneider A., Datta N.S., McCauley L.K. Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis. Cancer Res 2006;66:9065-73.
  3. Huggins C., Hodges C.V. Studies on prostatic cancer. I. The effect of castration, estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-97.
  4. Krupski T.L., Smith M.R., Brandman J., et al. Natural history of bone complications in men with prostate carcinoma in androgen deprivation therapy. Cancer 2004;101:541-49.
  5. Jiang H.X., Majumdar S.R., Dick D.A., et al. Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures. J Bone Miner Res 2005;20:494-500.
  6. Feldman D.J., Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-5.
  7. Mohler J.L., Gregory C.W., Ford O.H. 3rd., et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10(2):440-48.
  8. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003;423:337-42.
  9. Roodman G.D. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-64.
  10. Kostenuik P.J., Shalhoub V. Osteoprotegerin: A physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des 2001; 7:613-15.
  11. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93.
  12. Roodman G.D., Dougall W.C. RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev 2008;34(1):92-101.
  13. Saad F., Gleason D.M., Murray R., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-68.
  14. France World Health Organization (WHO). World Cancer Report 2008. International Agency for Research on Cancer, Lyon 2008.
  15. Norgaard M., Jensen A.O., Jacobsen J.B., et al. Skeletalrelated events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 2010;184(1):162-67.
  16. Schulman K.L., Kohles J. Economic burden of metastatic bone disease in the U.S. Cancer 2007;109(11):2334-42.
  17. Nakashima T., Hayashi M., Fukunaga T., et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 2011;17(10):1231-34.
  18. Smith M.R., Malkowicz S.B., Chu F., et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 2008;179:152-55.
  19. XGEVATM. Package insert. Thousand Oaks, CA: Amgen Inc, 2010.
  20. Smith M.R., Cook R., Lee K.A., Nelson J.B. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer 2010;published on-line Nov16.doi: 10.1002/cncr.25762.
  21. Smith M.R., Kabbinavar F., Saad F., et al. Natural history of rising serum prostate-specific antigen antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005; 23:2918-25.
  22. Stopeck A.T., Lipton A., Body J.J., et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28:5132-39.
  23. Fizazi K., Carduci M., Smith M., et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813-22.
  24. Lee R.J., Smith M.R. Osteoclast-targeted therapy for metastatic prostate cancer. Therapy 2008;5:63-72.
  25. Xiong J., Onal M., Jilka R.L., et al. Matrix-embedded cells control osteoclast formation. Nat Med 2011;17(10):1235-41.
  26. Lum L., Wong B.R., Josien R., et al. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 1999;274(19):13613-68.
  27. Kingsley L.A., Fournier P.G., Chirgwin J.M., Guise T.A. Molecular biology of bone metastasis. Mol Cancer Ther 2007;6(10):2609-17.
  28. Matthew R.S., Saad F., Coleman R., et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial November 16, 2011; published on-line DOl:10.1016/S0140-6736(11) 61226-29.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2012
##common.cookie##